London · Delayed Price · Currency is GBP · Price in GBX Genus Earnings Call Transcripts
Fiscal Year 2026
-
Adjusted PBT and EPS rose 35%, with £62m free cash flow and leverage down to 0.4x. FY 2027 guidance calls for moderate underlying profit growth, weighted to H2, while China JV and PRP commercialization advance.
-
Record first half profit driven by strong PIC growth, especially in China, and ABS margin improvement from VAP initiatives. Regulatory progress on PRP and the China JV formation position the group for long-term growth. FY26 adjusted PBT is expected to grow significantly.
Fiscal Year 2025
-
Strong financial and strategic progress was achieved, including robust profit growth, record free cash flow, and the accelerated PIC China JV. Market conditions are stable overall, with some headwinds in China, and significant growth in adjusted profit before tax is expected for FY26.
-
Strong H1 results with 19% adjusted operating profit growth and robust cash flow. Strategic progress includes PRP regulatory milestones, VAP benefits, and De Novo acquisition. Outlook remains positive, with stable markets but ongoing FX and regulatory risks.
Fiscal Year 2024
-
Structural strengthening and strategic progress achieved despite market headwinds, with robust royalty growth, cost savings from VAP, and improved second-half performance. Outlook for FY 2025 is positive, though cautious for China and with currency headwinds expected.
-
ABS margins remained at 4–5% in FY 2024, with transformation efforts targeting mid-teen margins. China profits declined due to economic and sector challenges, while PRP commercialization hinges on regulatory approvals in key export markets.